Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 06, 2018 01:00 ET | Source: Kuros Biosciences

Kuros Reports Publication of MagnetOs Data Demonstrating Equivalence to Autologous Bone in Spinal Fusion

Study should further enhance competitive positioning of MagnetOsSheep animal model is one of the most relevant preclinical models and believed to be predictive of outcomes in humans12-week fusion rate...
October 22, 2018 01:00 ET | Source: Kuros Biosciences

Kuros Biosciences Obtains US Patent Covering a Method for Producing Osteoinductive Materials

SCHLIEREN (ZURICH), Switzerland, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (SIX: KURN) announced today that its Dutch subsidiary, Kuros Biosciences BV, has recently been granted the US...
October 18, 2018 01:00 ET | Source: Kuros Biosciences

Kuros Biosciences Advances its Fibrin-PTH (KUR-113) Spinal Fusion Product Candidate Program

SCHLIEREN (ZURICH), Switzerland, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (SIX: KURN) announced today that the Company has reached a key milestone in its Fibrin-PTH (KUR-113) spinal...
September 27, 2018 11:30 ET | Source: Kuros Biosciences

Kuros Reports First Patient Treated in Randomized Controlled Trial of MagnetOs in Spinal Fusion

Kuros commercial activity focused on MagnetOs in spinal fusionStudy should further enhance competitive positioning of MagnetOs SCHLIEREN (ZURICH), Switzerland, Sept. 27, 2018 (GLOBE NEWSWIRE) --...
September 25, 2018 11:30 ET | Source: Kuros Biosciences

Kuros Biosciences Appoints Strategic Advisory Board

SCHLIEREN (ZURICH), Switzerland, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX: KURN) today announced the formation of its Strategic Advisory Board (SAB). The newly-formed SAB will work...
September 13, 2018 13:09 ET | Source: Kuros Biosciences

Kuros Biosciences to Host Key Opinion Leader Meeting on Establishing the New Gold Standard in Bone Regeneration

SCHLIEREN (ZURICH), Switzerland, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences, (SWX:KURN) a full-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone...
September 05, 2018 01:00 ET | Source: Kuros Biosciences

Kuros Biosciences Reports Results for First Half 2018

Financial highlights CHF 9.7 million cash at June 30Operating expenses decreased to CHF 6.0 million Operational highlights First U.S. & European sales of MagnetOsCommercial rollout in the U.S....
August 23, 2018 01:00 ET | Source: Kuros Biosciences

Kuros Biosciences Appoints Pascal Longlade as Chief Medical Officer

SCHLIEREN (ZURICH), Switzerland, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (SIX: KURN) announced today the appointment of Pascal Longlade as Chief Medical Officer, effective September...
July 02, 2018 01:00 ET | Source: Kuros Biosciences

Kuros Biosciences Reports First U.S. & UK sales of MagnetOs

Commercial Roll-Out in the U.S. & Europe On Track SCHLIEREN (ZURICH), Switzerland, July 02, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX:KURN) announced today it recorded the first...
June 19, 2018 01:00 ET | Source: Kuros Biosciences

Kuros Biosciences to Present Promising Clinical Case Studies with MagnetOs at Leading Spine Surgery Conference

SCHLIEREN (ZURICH), Switzerland, June 19, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX:KURN) will this week present results from several investigator-led clinical case studies of MagnetOs...